8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Dec 18, 2015)

Filed December 18, 2015For Securities:ALNY

Summary

This Form 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) reports a key change in its Board of Directors. Effective December 18, 2015, the size of the Board was expanded from ten to eleven members with the election of David E. I. Pyott. Mr. Pyott will serve as a Class II director, with his term scheduled to expire at the 2018 annual meeting of stockholders. The appointment of Mr. Pyott, a non-employee director, comes with a defined compensation structure. He will receive an annual cash fee of $50,000, a stock option grant to purchase 25,000 shares vesting over three years, and eligibility for future annual stock option awards. This move signals a potential strengthening of the board's expertise and oversight as Alnylam continues its development in the pharmaceutical sector.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members.
  • 2David E. I. Pyott was elected to fill the newly created vacancy on the Board.
  • 3Mr. Pyott's term as a Class II director is set to expire at the 2018 annual meeting of stockholders.
  • 4As a non-employee director, Mr. Pyott will receive an annual cash fee of $50,000.
  • 5Mr. Pyott received an initial stock option grant for 25,000 shares, vesting annually over three years.
  • 6He is eligible for future annual stock option awards for non-employee directors, subject to Compensation Committee determination and Board policy.
  • 7The company will reimburse Mr. Pyott for reasonable travel and related expenses incurred for his board service.

Frequently Asked Questions

David E. I. Pyott is a new non-employee director appointed to Alnylam's Board of Directors. While the filing doesn't detail his specific expertise, his appointment often signifies a desire to bring additional experience and strategic guidance to the company's leadership.

Mr. Pyott will receive an annual cash fee of $50,000. He was also granted an initial stock option to purchase 25,000 shares of common stock, which will vest over three years. Additionally, he is eligible for future annual stock option awards and reimbursement for related expenses.

The expansion of the board and the addition of a new director like Mr. Pyott can bring fresh perspectives, increased oversight, and potentially leverage new networks and expertise, which can be beneficial for a company at Alnylam's stage of development.

The immediate financial impact is limited to the compensation package for Mr. Pyott, which includes a $50,000 annual cash fee, the cost of the stock option grant (valued at fair market value on the grant date), and potential future option awards. These are standard costs associated with board membership and compensation for external directors.